Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01488344
Recruitment Status : Unknown
Verified December 2013 by University Hospital Muenster.
Recruitment status was:  Active, not recruiting
First Posted : December 8, 2011
Last Update Posted : December 11, 2013
Boehringer Ingelheim
Information provided by (Responsible Party):
University Hospital Muenster